As of 2024-12-13, the Intrinsic Value of Corline Biomedical AB (CLBIO.ST) is
89.85 SEK. This CLBIO.ST valuation is based on the model Discounted Cash Flows (EBITDA Exit 10Y).
With the current market price of 7.98 SEK, the upside of Corline Biomedical AB is
1,025.90%.
The range of the Intrinsic Value is (378.91) - 617.62 SEK
89.85 SEK
Intrinsic Value
CLBIO.ST Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(6,708.31) - (702.04) |
(1,256.15) |
-15841.2% |
| DCF (Growth 10y) |
(7,488.01) - (73,099.21) |
(13,544.63) |
-169832.2% |
| DCF (EBITDA 5y) |
(37.71) - 14.35 |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(378.91) - 617.62 |
89.85 |
1025.9% |
| Fair Value |
-2.24 - -2.24 |
-2.24 |
-128.09% |
| P/E |
(8.22) - (9.92) |
(9.87) |
-223.7% |
| EV/EBITDA |
(1.39) - 5.54 |
1.05 |
-86.8% |
| EPV |
(0.50) - (0.66) |
(0.58) |
-107.3% |
| DDM - Stable |
(7.98) - (2,190.03) |
(1,099.01) |
-13872.0% |
| DDM - Multi |
(26.56) - (5,650.96) |
(52.81) |
-761.8% |
CLBIO.ST Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
171.50 |
| Beta |
-1.03 |
| Outstanding shares (mil) |
21.49 |
| Enterprise Value (mil) |
164.16 |
| Market risk premium |
5.10% |
| Cost of Equity |
5.93% |
| Cost of Debt |
7.00% |
| WACC |
5.74% |